European Neuro Convention

15 - 16 September 2021
NEC, Birmingham

HEADLINE SPONSOR:

         circle rehabilitation                                       CPD Member

News & Press Releases

Wave Red Flow

25 Aug 2021

Supplements purposely developed to address the symptoms in patients with neurodegenerative diseases and improve the quality of life.

Αniva International among others is dedicated in developing, manufacturing and promoting products that can help patients with neurodegenerative and neurodevelopmental disorders.


NEUROASPIS probably the first patented combination and specially formulated dietary supplement in Europe used for medical purposes to support the MS patients in particular and patients with other related neurodegenerative diseases.


Through a diligent examination of the disease’s modus operandi through a systems medicine approach, the ingredients and their relative concentrations were chosen so the product provides the evident neuro-protective benefits. Its unique synthesis contains a mixture of the highest quality natural oils (Omega-3 and Omega-6 polyunsaturated fatty acids (PUFA)) and vitamins providing neuro-protective and cardio-protective benefits. In particular, the formulation contains scientifically studied dose and ratio of the required specific fatty acids such as omega-3 docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and omega-6 linoleic acid (LA) and gamma – linolenic acid (GLA).
Neuroaspis has a specialized activity as described below:


• Anti-inflammatory activity ➔ Reduces the arachidonic acid-induced inflammatory cytokines production and in parallel increases the anti-inflammatory cytokines.
• Antioxidant activity ➔ Increases the endogenous antioxidants and quenches the free radicals such as ROS and RNS.
• Neuroprotective and Neurotrophic activity ➔ Stimulates the receptor Nrf2 for neuroprotection and other receptors such as PPARg with neurotrophic function.


The functions of Neuroaspis are based on molecular pathways as proliferation, differentiation and migration of T-cells, regulation of metalloproteinase MMp-9 and permeability of blood brain barrier.


Due to its ingredients functions Neuroaspis help in reconstitution of cells’ membranes, leading to maximum cell communication. As a result, the stimulant is transferred more effectively and decreases the severity of the symptoms caused by bad cell communication. Along with cells’ membranes communication, Neuroaspis supports the function of mitochondria, which are the power plants of the cell leading to less fatigue. To that end, Neuroaspis deals with symptoms such as fatigue, atony, emotional changes, difficulties in morning wake-up, numbness and tingling.


In addition, Neuroaspis is a product of more than 10 years of research and clinical development, where the Clinical Study Phase II is finished and published in 2013 in BMJ. The proof-of-concept Phase II clinical trial was conducted under a stringent protocol with 80 patients. The clinical trial was conducted for a total period of 42 months, of which the 12 final months were post-intervention. The 12 months post-intervention highlight the positive effects of the formulation even in subsequent periods, and in fact pinpoint these positive effects to the ingredients used, as the period coincides with their flush-out period.


In conclusion, Neuroaspis with a compliance of at least 6 months addresses the symptoms of the disease and may delays the progress of the disease.

 

pic 2


SEDOASPIS is a product specifically designed to manage the non-motor symptoms of Parkinson's disease and Neurodevelopmental disorders. Sedoaspis is based on postbiotics that act on the Gut Brain Axi.

Parkinson's disease is a neurodegenerative disorder of the nervous system that affects movement. Symptoms begin gradually, and are distinguished into motor symptoms, and non-motor symptoms. Non-motor symptoms pre-exist the motor symptoms, and recent research has shown that they precede diagnosis. These include gastrointestinal disorders, sleep disorders, emotional fluctuations such as depression & anxiety and pain / stiffness. Non-motor symptoms accompany the patient's lifetime effect and largely determine the patient's quality of life.


Its unique synthesis contains the most available form of butyric acid, Tributyrin, saffron extract and vitamin D3. Butyric acid is one of the most known byproducts of microbiome (postbiotics), which is produced during food fermentation. Butyric acid plays an important role not only inside the intestine but also in different metabolic pathways. Saffron is a plant with great history and use. Saffron stigmas (the bioactive part of the plant) were used for cooking purposes but also for cosmetics, such as perfumery. These substances of saffron are responsible for its high bioactive character, with the most important, the antioxidant one. Vitamin D is a fat-soluble vitamin that plays an important role in immune system activation and modulation. The doses of the ingredients are scientifically studied on the requirements of the patients with Parkinson’s Disease and Neurodevelopmental disorders.


According to several clinical studies, Sedoaspis addresses the non-motor symptoms of Parkinson's disease through the following activities:

➢ Modulates inflammation
➢ Regulates mitochondrial dysfunction and supplies epithelium cells with energy
➢ Restores integrity and lowers intestinal permeability
➢ Increases dopamine synthesis through gut-brain axis
➢ Reduced the cortisol levels
➢ re-modulates neurotransmitter balance
➢ Reduces oxidative stress
➢ Supplies the organism with Vitamin D3

Based on the above mechanism of action Sedoaspis deals with the symptoms of Parkinson’s Disease such as gastrointestinal disorders, sleep disorders, emotional fluctuations, fatigue pain and stiffness.


Clinical studies have shown that patients with Parkinson's disease have very low levels of butyric acid compared to healthy individuals as there is a disturbance in the balance of the intestinal microbial flora. Decreased levels of butyrate have the effect of disrupting gastrointestinal function and deregulating the levels of neurotransmitters such as serotonin and dopamine. In addition, by regulating the levels of vitamin D, Sedoaspis contributes to the reduction of stiffness and pain, which are basic non-motor symptoms of the disease. As noted in several studies, vitamin D is involved in different pathways such as protein production and the production of anti-inflammatory cytokines. Finally, the saffron extract, through the special antioxidant mechanism for neurodegenerative diseases and neurodevelopmental disorders, helps to the reduction of cortisol levels and sleep disorders as reported in numerous clinical studies.


In conclusion, Sedoaspis is a novel nutritional supplement for the treatment of the non-motor symptoms of patients with Parkinson’s Disease and Neurodevelopmental Disorders.


For more information please contact:
info@aniva-int.com

View all News & Press Releases
Loading